Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

Author(s): Francis J. Giles, Maher Albitar

Journal Name: Current Molecular Medicine

Volume 5 , Issue 7 , 2005

Become EABM
Become Reviewer
Call for Editor


Reflecting its critical role in integrating cell growth and division with the cellular nutritional environment, the mammalian target of rapamycin *(mTOR) is a highly conserved downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway. mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E-binding protein-1. As a consequence of inhibiting its downstream messengers, mTOR inhibitors prevent cyclindependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause GI phase arrest. Constitutive activation of the PI3K/Akt kinases occur in human leukemias. FLT3, VEGF, and BCR-ABL mediate their activities via mTOR. New rapamycin analogs including CCI- 779, RAD001, and AP23573, are entering clinical studies for patients with hematologic malignancies.

Keywords: mTOR, leukemia, phosphatidylinositol 3' kinase, AKT, CCI-779, RAD001, AP23573

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Published on: 01 March, 2012
Page: [653 - 661]
Pages: 9
DOI: 10.2174/156652405774641034
Price: $65

Article Metrics

PDF: 4